MarginsXMarginsX
Home › Markets › Health Care › LYEL

Lyell Immunopharma Inc. (LYEL)

LYEL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$14.65
+2.45% on the day
Market cap
$469.0M
Small cap
Revenue · 2025
$36K
-41.0% on 2024
Net income · 2025
-$274.4M
-762355.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1806952/000162828026017253/0001628280-26-017253-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLYEL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001806952
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$36K
Net income-$274.4M
Operating income-$269.4M
Net margin-762355.6%
Operating margin-748344.4%
Revenue growth-41.0%
Cash$60.2M
Total assets$340.1M
P/E (computed)Net income was not positive
P/S (computed)13028.6×

Warning signs

Cash runway
7.9 months
$92.1M cash at September 30, 2026
Share count, 1 year
+15.9%
2025-11-10 to 2026-10-30 · +95.2% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$11.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$92.1M cash; operating cash flow -$34.8M a quarter.Report 2026-09-30
Shares outstanding24,585,565 (2026-10-30); 21,218,217 a year earlier; 251,868,968 three years earlier. 3y figure adjusted for split (1-for-20 overall).Cover page 2026-10-30
Reverse splits, 3 years1; latest 1-for-20 on 2025-06-02Source 2025-06-02
Shelf and offerings, 12 months4 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2025-12-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $12.5M, sold $605K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$3K-$45.5M-$34.6M$92.1MNo debt tags$15K10-Q 2026-11-04
Q2 2026
2026-06-30
$4K-$44.8M-$33.9M$73.0MNo debt tags$27K10-Q 2026-08-06
Q1 2026
2026-03-31
$2K-$24.2M-$38.5M$90.8MNo debt tags$31K10-Q 2026-05-06
Q4 2025
2025-12-31
$6K-$140.7M-$32.3M$60.2MNo debt tags$36K10-K 2026-03-12
Q3 2025
2025-09-30
$15K-$38.8M-$28.6M$123.6MNo debt tags$41K10-Q 2026-11-04
Q2 2025
2025-06-30
$8K-$42.7M-$34.5M$98.8MNo debt tags$60K10-Q 2026-08-06
Q1 2025
2025-03-31
$7K-$52.2M-$54.7M$120.3MNo debt tags$65K10-Q 2026-05-06
Q4 2024
2024-12-31
$11K-$191.9M-$47.2M$105.6MNo debt tags$61K10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-13
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 365 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.8%
1 month+90.4%
3 months+4.1%
Year to date-53.5%
1 year-17.9%
From 52-week high-63.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OCSOculis Holding AG$7.63-0.13%$469.9M
KMDAKamada Ltd.$8.11+0.25%$468.0M
AQSTAquestive Therapeutics Inc.$3.76-3.84%$472.6M
STTKShattuck Labs Inc.$4.66+0.21%$474.6M
PHATPhathom Pharmaceuticals Inc.$5.88-2.97%$478.0M
NGNENeurogene Inc. Common Stock$23.30-2.63%$482.3M
CAPRCapricor Therapeutics Inc.$8.30-12.91%$482.6M
OVIDOvid Therapeutics Inc.$2.40-5.51%$453.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier